Endo Claims Opana Generic Versions Ripe For Misuse, Abuse

Law360, New York (December 3, 2012, 3:06 PM EST) -- Endo Pharmaceuticals Inc. on Friday urged a judge to force the U.S. Food and Drug Administration to determine whether the drugmaker voluntarily yanked the original version of its Opana ER painkiller from the market over tampering and abuse concerns and to suspend approval of nontamper-resistant generic versions.

Endo voluntarily recalled the original version of Opana ER in May after determining that it was susceptible to misuse and abuse — usually by crushing and snorting the pills — and a safety risk, according to a complaint and...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

ENDO PHARMACEUTICALS INC. v. MARGARGET HAMBURG, et al


Case Number

1:12-cv-01936

Court

District Of Columbia

Nature of Suit

P.I.: Other

Judge

Reggie B. Walton

Date Filed

November 30, 2012

Law Firms

Companies

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.